Sinovac Biotech Ltd. develops, manufactures and commercializes vaccines and related biological products for human infectious diseases. The China-based biopharmaceutical company’s marketed portfolio includes vaccines for influenza, viral hepatitis, varicella, hand-foot-mouth disease associated with EV71, poliomyelitis, pneumococcal disease and COVID-19, and its pipeline includes combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Company updates commonly address vaccine sales, research and development progress, product approvals, overseas market activity and financial reporting. Recent corporate developments also include Nasdaq listing-compliance matters, auditor engagement, SEC filing status and governance proceedings involving board composition and shareholder-meeting disputes.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its subsidiary, Sinovac Life Sciences Co., Ltd., secured approximately $500 million in funding from Sino Biopharmaceutical Limited. This investment grants Sino Biopharmaceutical approximately 15% equity interest in Sinovac LS and aims to enhance the development and manufacturing capabilities for the COVID-19 vaccine, CoronaVac. With ongoing Phase III trials approved in several countries, Sinovac anticipates annual production capacity of 600 million doses after expansion. The funding is expected to accelerate Sinovac's efforts against the pandemic.
Sinovac Biotech Ltd. (NASDAQ:SVA) announced that the Beijing Fourth Intermediate Court found Sinobioway Medicine and Mr. Aihua Pan liable for torts and breaches of fiduciary duty. The court ruling stemmed from a 2018 complaint by Sinovac Hong Kong concerning an attempt to take control of Sinovac’s facility, which led to product destruction valued at RMB15.404 million. The ruling allows for an appeal within 15 days by the defendants or 30 days by the plaintiff. Sinovac continues to focus on developing and selling vaccines in China and internationally.